{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T17:34:24Z","timestamp":1776188064747,"version":"3.50.1"},"reference-count":46,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2023,8,3]]},"DOI":"10.1080\/13543784.2023.2252738","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T12:30:01Z","timestamp":1693312201000},"page":"677-683","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS)"],"prefix":"10.1080","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4064-6554","authenticated-orcid":false,"given":"J. Daniel","family":"Bireley","sequence":"first","affiliation":[{"name":"Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-9547","authenticated-orcid":false,"given":"John A.","family":"Morren","sequence":"additional","affiliation":[{"name":"Neuromuscular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,9]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01272-7"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12408"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2015.1039941"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2013.864312"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181bc0141"},{"key":"e_1_3_4_8_1","volume-title":"Motor neurone disease: assessment and management","author":"National Institute for Health and Care Excellence (NICE)","year":"2019","unstructured":"National Institute for Health and Care Excellence (NICE). Motor neurone disease: assessment and management. London: National Institute for Health and Care Excellence (NICE);2019 Jul ."},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191721"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91680-3"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403033300901"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt085"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30115-1"},{"key":"e_1_3_4_14_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/21678421.2017.1363780","article-title":"A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis","volume":"18","author":"Abe K","year":"2017","unstructured":"Abe K, Itoyama Y, Tsuji S, et al. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:11\u201319.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21528"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2020.1746809"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004427.pub4"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2020.1771734"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30054-1"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26740"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09993-z"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4893"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1054006"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916945"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-329024"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204705"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01237-4"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26285"},{"key":"e_1_3_4_29_1","unstructured":"Biohaven Provides Update From Pivotal Phase 2\/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial) | Small Molecules | News Channels. [cited 2023 May 3]. Available from: https:\/\/pipelinereview.com\/index.php\/2022093081723\/Small-Molecules\/Biohaven-Provides-Update-From-Pivotal-Phase-2\/3-Trial-with-Verdiperstat-in-Amyotrophic-Lateral-Sclerosis-Healy-ALS-Platform-Trial.html"},{"key":"e_1_3_4_30_1","unstructured":"The HEALEY ALS Platform Trial completes enrollment for Regimen E evaluating SLS-005 (Trehalose) by Seelos Therapeutics. [cited 2023 May 3]. Available from: https:\/\/www.massgeneral.org\/neurology\/als\/news\/healey-center-regimen-e-2023"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041479"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58709-w"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.698779"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.08.003"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.38487"},{"issue":"1","key":"e_1_3_4_36_1","first-page":"239","article-title":"Redox-enhancing nanocatalysis improves motor neuron survival in vitro and SOD1 mouse motor function and survival in vivo","volume":"20","author":"Ho HS","year":"2019","unstructured":"Ho HS, Zhang JZ, Richard JP, et al. Redox-enhancing nanocatalysis improves motor neuron survival in vitro and SOD1 mouse motor function and survival in vivo. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(Supplement 1):239.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"e_1_3_4_37_1","unstructured":"CNM-Au8 Gold Nanocatalysis Protects Neurons Against Degeneration and Death in Multiple in vitro Models of Amyotrophic Lateral Sclerosis - MDA Clinical & Scientific Conference 2023. [cited 2023 May 3]. Available from: https:\/\/www.mdaconference.org\/abstract-library\/cnm-au8-gold-nanocatalysis-protects-neurons-against-degeneration-and-death-in-multiple-in-vitro-models-of-amyotrophic-lateral-sclerosis\/"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.01310"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1101\/2023.05.11.23289871"},{"key":"e_1_3_4_40_1","unstructured":"CNM-Au8 | ALZFORUM. [cited 2023 May 3]. Available from: https:\/\/www.alzforum.org\/therapeutics\/cnm-au8"},{"key":"e_1_3_4_41_1","doi-asserted-by":"crossref","first-page":"102036","DOI":"10.1016\/j.eclinm.2023.102036","article-title":"Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension","volume":"60","author":"Vucic S","year":"2023","unstructured":"Vucic S, Menon P, Huynh W, et al. Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension. EClinicalMedicine. 2023;60:102036.","journal-title":"EClinicalMedicine"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-310509"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21824"},{"key":"e_1_3_4_44_1","unstructured":"Clene Inc. Clene Nanomedicine announces top-line results from phase 2 RESCUE-ALS clinical trial. [cited 2023 May 3]. Available from: https:\/\/invest.clene.com\/news-releases\/news-release-details\/clene-nanomedicine-announces-top-line-results-phase-2-rescue-als"},{"key":"e_1_3_4_45_1","volume-title":"ENCALS Annual Meeting","author":"Vucic S","year":"2022","unstructured":"Vucic S, Menon P, Huynh W, et al. RESCUE-ALS trial results: a phase 2, randomized, double-blind, placebo-controlled study of CNM-Au8 to slow disease progression in ALS. ENCALS Annual Meeting; Jun 1-3, 2022; Edinburgh, Scotland, UK."},{"key":"e_1_3_4_46_1","volume-title":"AANEM Annual Meeting","author":"Vucic S","year":"2022","unstructured":"Vucic S, Menon P, Huynh W, et al. RESCUE-ALS trial results: a phase 2, randomized, double-blind, placebo-controlled study of CNM-Au8 to slow disease progression in ALS. AANEM Annual Meeting; Sep 21-24, 2022; Nashville, TN, USA."},{"key":"e_1_3_4_47_1","unstructured":"Clene Inc. Clene reports topline results demonstrating survival signal for CNM-Au8\u00ae in healey ALS Platform trial. [cited 2023 May 3]. Available from: https:\/\/invest.clene.com\/news-releases\/news-release-details\/clene-reports-topline-results-demonstrating-survival-signal-cnm."},{"key":"e_1_3_4_48_1","unstructured":"Clene Inc. CNM-Au8\u00ae associated with delayed time to key clinical progression events at six months supporting a survival benefit in the healey ALS Platform trial. [cited 2023 May 3]. Available from: https:\/\/invest.clene.com\/news-releases\/news-release-details\/cnm-au8r-associated-delayed-time-key-clinical-progression-events"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2023.2252738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T17:08:41Z","timestamp":1695316121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2023.2252738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,3]]}},"alternative-id":["10.1080\/13543784.2023.2252738"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2023.2252738","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}